Thyroid nodule classification: Difference between revisions
No edit summary |
No edit summary |
||
Line 57: | Line 57: | ||
!Origin | !Origin | ||
!histologic subtypes | !histologic subtypes | ||
! | !Subclass | ||
|- | |- | ||
| rowspan="4" |Nonmedullary thyroid cancers (NMTCs) | | rowspan="4" |Nonmedullary thyroid cancers (NMTCs) | ||
Line 173: | Line 173: | ||
==== Thyroid nodule classification based on the sonographhic features: ==== | ==== Thyroid nodule classification based on the sonographhic features: ==== | ||
Classification system has been proposed by Horvath et | Classification system has been proposed by Horvath et al, with a modified recommendation from Jin Kwak et al.<ref name="pmid19276237">{{cite journal |vauthors=Horvath E, Majlis S, Rossi R, Franco C, Niedmann JP, Castro A, Dominguez M |title=An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management |journal=J. Clin. Endocrinol. Metab. |volume=94 |issue=5 |pages=1748–51 |year=2009 |pmid=19276237 |doi=10.1210/jc.2008-1724 |url=}}</ref> | ||
{| class="wikitable" | {| class="wikitable" | ||
! colspan="2" | | ! colspan="2" | |
Revision as of 19:41, 28 August 2017
Thyroid nodule Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Thyroid nodule classification On the Web |
American Roentgen Ray Society Images of Thyroid nodule classification |
Risk calculators and risk factors for Thyroid nodule classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]
Bethesda System for Reporting Thyroid Cytopathology
classification | FNA cytology | Predicted risk of malignancy |
---|---|---|
Benign |
|
0–3 % |
Nondiagnostic or Unsatisfactory | 1–4 % | |
Follicular lesion of undetermined significance |
|
5–15 % |
Atypia of undetermined significance |
| |
Follicular neoplasm |
|
15–30 % |
Suspicious for a follicular neoplasm |
|
60–75 % |
Malignant |
|
97–99 % |
Classification of neoplastic thyroid nodules based on their origin:
Origin | histologic subtypes | Subclass | ||
---|---|---|---|---|
Nonmedullary thyroid cancers (NMTCs) | 95% of tumors | thyroid epithelial cells | papillary (85%) | 95% are sporadic tumors
5% may be related to inherited genetics due to familial origin
|
follicular (11%) |
| |||
Hürthle cell (3%) | ||||
anaplastic (1%) | ||||
Medullary thyroid cancers (MTCs) | 5% of all thyroid malignancies | calcitonin-producing parafollicular cells | 20% they are familial and occur as part of the multiple endocrine neoplasia (MEN) syndromes |
Of the differentiated cancers, papillary cancer comprises about 85% of cases compared to about 10% that have follicular histology, and 3% that are Hu¨rthle cell or oxyphil tumors
Neoplastic thyroid nodules subclassification:
Neoplasm | Subclass | Features | |
---|---|---|---|
Follicular thyroid lesions | Benign follicular adenoma | ||
Minimally invasive follicular carcinoma | only invasion of the capsule of the tumor without vascular invasion | ||
Widely invasive follicular carcinoma |
|
||
Encapsulated follicular variant of papillary thyroid cancer | minor vascular invasion (≤4 foci of angioinvasion within the tumor or capsule of the tumor) with or without capsular invasion | ||
Infiltrative variant of papillary thyroid cancer | |||
papillary thyroid cancer | Classic varient | ||
tall cell variant | more aggressive tumor than classical papillary cancer
tumor cells with eosinophilic cytoplasm that are twice as tall as they are wide. The primary tumors tend to be large, they are often invasive, and many patients have both local and distant metastases at the time of diagnosis |
||
insular varient | solid nests of tumor, often separated by fibrous bands, but the tumor cell nuclei have the same characteristics as do the nuclei of classical papillary cancers. | ||
columnar variant | elongated cells with palisading nuclei. | ||
Hürthle or oxyphilic variant | Cellular features of Hürthle cell carcinomas but cells that are arranged in papillary formations. | ||
solid or trabecular variant | |||
clear cell variant | must be distinguished from clear cell carcinomas of other organs such as the kidney or colon that have metastasized to the thyroid. | ||
diffuse sclerosing variant | diffuse involvement of the thyroid, stromal fibrosis, and prominent lymphocytic infiltration | ||
cribriform morular variant | Prominent cribriform pattern with solid and spindle cell areas as well as squamous morules. This variant is often associated with familial adenomatous polyposis. | ||
hobnail variant | harbors BRAF V600E mutations and appears to be associated with a high risk of distant metastases and an increased disease-specific mortality |
Thyroid nodule classification based on the sonographhic features:
Classification system has been proposed by Horvath et al, with a modified recommendation from Jin Kwak et al.[2]
TIRADS 1 | Normal thyroid gland | |||
TIRADS 2 | Benign lesions |
|
0% risk of malignancy | |
TIRADS 3 | Probably benign lesions |
|
<5% risk of malignancy | |
TIRADS 4 | 4a | One suspicious feature |
|
5-10% risk of malignancy |
4b | Two suspicious features | 10-80% risk of malignancy | ||
4c | Three/four suspicious features | |||
TIRADS 5 | All five suspicious features | Probably malignant lesions (more than 80% risk of malignancy) | >80% risk of malignancy | |
TIRADS 6 | Biopsy proven malignancy |
Classification based on TNM
Differentiated and anaplastic thyroid carcinoma TNM staging AJCC UICC 2017
Papillary, follicular, poorly differentiated, Hurthle cell and anaplastic thyroid carcinoma | ||||||||
Primary tumor (T) | Regional lymph nodes (N) | Distant metastasis (M) | ||||||
T category | T criteria | N category | N criteria | M category | M criteria | |||
TX | Primary tumor cannot be assessed | NX | Regional lymph nodes cannot be assessed | M0 | No distant metastasis | |||
T0 | No evidence of primary tumor | N0 | No evidence of locoregional lymph node metastasis | M1 | Distant metastasis | |||
T1 | Tumor ≤2 cm in greatest dimension limited to the thyroid | N0a | One or more cytologically or histologically confirmed benign lymph nodes | |||||
T1a | Tumor ≤1 cm in greatest dimension limited to the thyroid | N0b | No radiologic or clinical evidence of locoregional lymph node metastasis | |||||
T1b | Tumor >1 cm but ≤2 cm in greatest dimension limited to the thyroid | N1 | Metastasis to regional nodes | |||||
T2 | Tumor >2 cm but ≤4 cm in greatest dimension limited to the thyroid | N1a | Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease. | |||||
T3 | Tumor >4 cm limited to the thyroid, or gross extrathyroidal extension invading only strap muscles | N1b | Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes (levels I, II, III, IV, or V) or retropharyngeal lymph nodes | |||||
T3a | Tumor >4 cm limited to the thyroid | |||||||
T3b | Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size | |||||||
T4 | Includes gross extrathyroidal extension | |||||||
T4a | Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size | |||||||
T4b | Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size |
References
- ↑ Cibas ES, Ali SZ (2009). "The Bethesda System for Reporting Thyroid Cytopathology". Thyroid. 19 (11): 1159–65. doi:10.1089/thy.2009.0274. PMID 19888858.
- ↑ Horvath E, Majlis S, Rossi R, Franco C, Niedmann JP, Castro A, Dominguez M (2009). "An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management". J. Clin. Endocrinol. Metab. 94 (5): 1748–51. doi:10.1210/jc.2008-1724. PMID 19276237.